Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2000

View Archived Issues

Creative BioMolecules' OP-1 Implant enters regulatory review process during Q3 1999

Cell Genesys receives payment from Japan Tobacco

Phase II study of Fabry's disease treatment successfully completed

Medarex and IDM establish broad collaborative agreement

Interneuron signs major partnerships and focuses resources during 1999

Company Profile: Onyvax

Levotech completes phase IIb study of seven-day contraceptive patch

Cell Based Delivery receives NIST grant for cardiovascular program

Immunomedics/IBC develop new fusion protein for use in cancer therapy

Incara completes sale of antibacterial division

Nonpeptide endothelin antagonists from Warner-Lambert selective for ETA receptors

Abbott investigates new compounds for angiogenesis-related disorders

Preparation and use of MMP inhibitors described by Bayer

Merck describes thrombin-specific anticoagulants

Centaur's new NRTs and their use for treating, preventing IBD

Phenylalanine derivatives selective for alpha4 integrins discovered by Celltech

Specific VLA-4 inhibitor designed at Biogen for cell adhesion-mediated pathologies

Metabotropic glutamate receptor agonist tested in anxiety and addiction models

SmithKline Beecham patents novel ERK/MAP kinase inhibitors

NDA filed for intranasal scopolamine during fourth quarter

Antiangiogenic activity of troponin I may involve direct inhibition of bFGF and VEGF receptors

CFC-free flunisolide to be developed by 3M/Forest partnership

ViroPharma licenses Battelle's drug delivery technology for its anti-RSV products

Preclinical pharmacokinetics of SB-240563 support clinical development for asthma

Potent new nonpeptide bradykinin B2 receptor antagonist selected by Fournier for further development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...